Clinical Trial Results:
Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR)
Summary
|
|
EudraCT number |
2015-003723-65 |
Trial protocol |
GB |
Global end of trial date |
20 Nov 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Jun 2019
|
First version publication date |
20 Jun 2019
|
Other versions |
|
Summary report(s) |
Final study report |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MICM1014
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02661711 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Moorfields Eye Hospital
|
||
Sponsor organisation address |
162 City Road, London, United Kingdom, EC1V 2PD
|
||
Public contact |
Gisela Barreto, Moorfields Eye Hospital, +44 02072533411, gisela.barreto@moorfields.nhs.uk
|
||
Scientific contact |
Gisela Barreto, Moorfields Eye Hospital, +44 02072533411, gisela.barreto@moorfields.nhs.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
20 Nov 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
20 Nov 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Nov 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To report mean Central Macular Thickness (CMT) at 6 and 12 months as measured with SDOCT in eyes of patients with Retinitis Pigmentosa associated with cystoid macular oedema treated with three loading doses of Eylea at monthly intervals followed by a treat and extend protocol between baseline and twelve months.
|
||
Protection of trial subjects |
Non-study eye was treated in accordance with NHS standards of care and was monitored throughout the study.
|
||
Background therapy |
Patients stopped topical and/or oral treatment for retinitis pigmentosa-associated cystoid macular oedema (RP-CMO) in the study eye whilst undertaking this study. Topical treatment in the non-study eye could be continued throughout the study if the patient wished to continue this. | ||
Evidence for comparator |
The study drug was not compared to another drug during this trial | ||
Actual start date of recruitment |
14 Mar 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 30
|
||
Worldwide total number of subjects |
30
|
||
EEA total number of subjects |
30
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
30
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
Patients will be recruited over a 6 to 12 month period. Within a week of being approached in the medical retina clinics or by telephone and having been provided with information about the trial, our research manager will contact the patient and invite them to attend a screening appointment. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
130 patients were found to be suitable participants. 18 could not be contacted, 1 was deceased, 32 wished to be considered for the study, and 79 others declined for various reasons. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Not applicable
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Blinding implementation details |
Not blinded
|
||||||||||
Arms
|
|||||||||||
Arm title
|
Intravitreal aflibercept for RP-CMO | ||||||||||
Arm description |
Intravitreal aflibercept for RP-CMO | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
Aflibercept
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Concentrate for suspension for injection
|
||||||||||
Routes of administration |
Intravitreal use
|
||||||||||
Dosage and administration details |
Eylea solution is supplied in a vial (40mg/ml). Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. This provides a usable amount to deliver a single dose of 50 microlitres containing 2 mg aflibercept. The dose used in this trial will be 0.05ml (2mg) per intravitreal injection.
|
||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Overall cohort
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The overall cohort
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Responders
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients who were deemed as 'responders'
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intravitreal aflibercept for RP-CMO
|
||
Reporting group description |
Intravitreal aflibercept for RP-CMO | ||
Subject analysis set title |
Overall cohort
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
The overall cohort
|
||
Subject analysis set title |
Responders
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Patients who were deemed as 'responders'
|
|
||||||||||
End point title |
Mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline [1] | |||||||||
End point description |
To report the efficacy of aflibercept in RP-CME via mean central macular thickness (CMT) on Spectral domain OCT (SDOCT) at 12 months after baseline.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
12 months
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive statistics were used for this study |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
12 months
|
||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
Bayer plc., 2015 | ||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
Serious adverse event
|
||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0.05% | |||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
09 Dec 2015 |
We requested to analyse data at 6 months as well as at 12 months |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
N/A |